On this page
GABRB1
gamma-aminobutyric acid type A receptor subunit beta1
GABRB1 encodes a subunit of GABA-A receptors, which regulate inhibitory signalling in the brain and are implicated in epilepsy when disrupted. The GABRB1 gene provides instructions for making the beta-1 subunit of GABA-A receptors, protein complexes that mediate the brain's primary inhibitory neurotransmitter system.
GABRB1 is located on the short (p) arm of chromosome 4, at band 4p12. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 4 in the library →Overview
GABRB1 encodes the gamma-aminobutyric acid type A receptor subunit beta1, a component of GABA-A receptors found throughout the central nervous system. These receptors form chloride channels that respond to GABA, the brain's principal inhibitory neurotransmitter, helping to regulate neuronal excitability and maintain the balance between excitation and inhibition. Pathogenic variants in GABRB1 are associated with epilepsy syndromes, particularly those with early onset. The gene is located on chromosome 4p12 and follows an autosomal dominant inheritance pattern, meaning a single altered copy can be sufficient to cause disease.
What the gene does
The GABRB1 protein is one of several subunits that assemble to form GABA-A receptors, pentameric ion channels embedded in neuronal membranes. When GABA binds to these receptors, the channel opens to allow chloride ions to flow into the neuron, making the cell less likely to fire an action potential. This inhibitory mechanism is essential for preventing excessive neuronal activity and maintaining normal brain function. The beta-1 subunit contributes to the receptor's structural integrity and influences its sensitivity to GABA, as well as its response to modulatory compounds. Different combinations of alpha, beta, gamma, and other subunits produce receptor subtypes with distinct pharmacological properties and regional distributions in the brain. GABRB1-containing receptors are particularly abundant in certain cortical and subcortical regions where they help control the threshold for seizure activity.
Video: Genetics 101
Chromosome location
GABRB1 is located on the short arm of chromosome 4 at position p12 (4p12). This chromosomal region also contains several other genes involved in neurodevelopment. The gene spans multiple exons that encode a protein of 474 amino acids.
Protein structure
Domain architecture has not been experimentally characterised in detail for this protein. The GABRB1 subunit shares the general topology of ionotropic receptor subunits, with an extracellular N-terminal domain involved in ligand binding and subunit assembly, four transmembrane segments that form the ion channel pore, and intracellular loops that provide sites for modulation by phosphorylation and interaction with scaffolding proteins.
Key variants
Pathogenic variants in GABRB1 typically result in loss of receptor function through mechanisms including impaired subunit folding, reduced surface expression, or altered channel gating properties. Most disease-causing variants are missense changes that substitute critical amino acids, though small deletions and insertions have also been reported. The variant landscape reflects the gene's autosomal dominant pattern, with many pathogenic alleles arising de novo rather than being inherited.
Sample of pathogenic variants
5 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.737T>C | p.Phe246Ser | Pathogenic | - | Developmental and epileptic encephalopathy, 45 |
c.157C>T | p.Arg53Trp | Likely pathogenic | ★☆☆☆ | Developmental and epileptic encephalopathy, 45 |
c.740T>C | p.Ile247Thr | Likely pathogenic | ★☆☆☆ | Developmental and epileptic encephalopathy, 45 |
c.854C>A | p.Thr285Lys | Likely pathogenic | ★☆☆☆ | Developmental and epileptic encephalopathy, 45 |
c.860C>T | p.Thr287Ile | Likely pathogenic | ★☆☆☆ | Developmental and epileptic encephalopathy, 45 |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Variants in GABRB1 are primarily associated with epilepsy syndromes characterised by early onset and, in many cases, developmental features. Affected individuals may present with infantile spasms, generalised seizures, or focal epilepsy, often accompanied by developmental delay or intellectual disability. The severity and specific phenotype can vary considerably, even among individuals with the same variant, reflecting the influence of genetic background and environmental factors on disease expression. Management of GABRB1-related epilepsy is individualised and typically led by a paediatric or adult neurologist, often in partnership with clinical genetics. Treatment usually involves antiepileptic medications chosen according to seizure type and the overall clinical picture, and some GABRB1-related epilepsies can be difficult to control with standard therapies (drug-resistant epilepsy). Additional support for developmental, learning, or behavioural needs is often part of broader care. Specific treatment decisions, prognosis, and family planning considerations should be discussed with your own clinical team, who can take your individual circumstances into account.
No disease links recorded for this gene in our reference set.
Inheritance pattern
Conditions caused by pathogenic GABRB1 variants typically follow autosomal dominant inheritance.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
UK clinical status
GABRB1 is included on the NHS Genomic Medicine Service Early Onset or Syndromic Epilepsy panel with green classification (level R59), indicating strong evidence for its role in epilepsy. This panel guides genetic testing for individuals with seizures beginning in infancy or childhood, particularly when accompanied by developmental concerns or features suggesting a genetic cause. A green rating means there is strong clinical validity for including this gene in diagnostic testing. In practice, testing is typically accessed via referral from a paediatrician, neurologist, or clinical geneticist following clinical assessment, rather than being requested directly by patients or families.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Diet & lifestyle considerations
No specific lifestyle modifications have been shown to modify the risk or course of GABRB1-related epilepsy. General epilepsy safety measures - such as identifying and avoiding personal seizure triggers, maintaining regular sleep, and taking practical precautions around activities like swimming or bathing - should be discussed with your neurology team, who can tailor advice to your individual situation.
Supplement considerations
No supplements have been shown to treat or prevent GABRB1-related epilepsy. Any vitamins, minerals, or over-the-counter products should be discussed with your clinical team first, as some can interact with antiepileptic medications. This page is educational only and is not a substitute for medical advice.
Frequently asked questions
What inheritance pattern does GABRB1 follow?
GABRB1 follows an autosomal dominant pattern, meaning a pathogenic variant in one copy of the gene can cause disease. Many cases arise from new (de novo) variants not inherited from either parent.
How does GABRB1 relate to epilepsy?
GABRB1 encodes a subunit of GABA-A receptors, which dampen neuronal excitability. When variants disrupt receptor function, the balance between excitation and inhibition in the brain is altered, increasing susceptibility to seizures.
Is genetic testing for GABRB1 available on the NHS?
Yes, GABRB1 is included on the NHS Early Onset or Syndromic Epilepsy panel (R59). Testing is available through the NHS Genomic Medicine Service for individuals with appropriate clinical features, and is usually arranged by a paediatrician, neurologist, or clinical geneticist after a clinical assessment.
How is GABRB1-related epilepsy treated?
Treatment is individualised and should be guided by a neurology team. It often includes antiepileptic medications chosen according to seizure type, alongside support for any developmental or learning needs. Some GABRB1-related epilepsies can be drug-resistant, so specialist input is important. Discuss specific options and prognosis with your own clinical team.